Mouse mammary tumor virus (MMTV) is associated primarily with mammary carcinomas and lymphomas. The signal peptide of the MMTV envelope precursor is uniquely targeted to nucleoli of cells that harbor the virus, where it can function as a nuclear export factor for intron-containing transcripts. Antibodies to this signal peptide, which we refer to as p14, were previously shown to label nucleoli in a subset of human breast cancers. To look for additional cellular functions of p14, different mutants were ectopically expressed in the MCF-7 human breast cancer cell line. This approach identified motifs responsible for its nucleolar targeting, nucleocytoplasmic shuttling, target protein (B23, nucleophosmin) binding, and phosphorylation at serine 18 and 65 both in situ and in vitro. To test the role of these phosphorylation sites, we carried out in vivo tumorigenesis studies in severe combined immunodeficient mice. The findings show that the p14-Ser65Ala mutation is associated with impaired tumorigenicity, whereas the p14-Ser18Ala mutation is associated with enhanced tumorigenicity. Microarray analysis suggests that phosphorylation at serine 18 or at serine 65 is associated with transcriptional regulation of the L5 nucleolar ribosomal protein (a p14 target) and the Erb-B signal transduction pathway. Taken together, these results show that the phosphorylation status of p14 determines whether it functions as a pro-oncogenic or antioncogenic modulator.
Introduction
Mouse mammary tumor virus (MMTV) is a type B retrovirus associated primarily with mammary carcinomas and lymphomas in laboratory mice (1, 2) . During the 1970s, MMTV was suggested to play a role in the etiology of human breast cancer when claims were first made that MMTV antigens were involved in this disease (3) . A new wave of interest in this issue started in the mid-1990s when MMTV DNA sequences were first identified, using PCR technology, in 38% of human breast cancer samples, but not in healthy tissue (4) . Despite the lack of incontrovertible evidence for a causal relationship between MMTV and breast cancer and doubts whether MMTV is a tumor virus or just a "rumor" virus in the context of this disease (ref. 5 ; and references therein), a number of reports from different groups do suggest an association between MMTV (or HMTV-human mammary tumor virus) sequences and breast cancer in up to 74% of women with the disease (related to geographical distribution; refs. [6] [7] [8] . Indeed, it has recently been reported (9) that inflammatory breast cancers from American women show a higher incidence of HMTV-related viral sequences (71%) than sporadic breast cancers, and that the presence of MMTV-env-like exogenous sequences is strictly related to tumor progression (10) . Additional support for possible involvement of the virus in breast cancer comes from reports claiming that MMTV can infect and spread through a culture of human mammary cells (11, 12) ; the MMTV env protein, through a specific sequence motif, can initiate changes that are consistent with transformation of mammary epithelial cells (13) ; cells isolated from ascites or pleural effusions of patients with metastatic breast cancer contained MMTV sequences in their DNA, expressed the MMTV Env protein and showed b-retroviral particles by electron microscopy, similar to the mouse virus (14) . The same group recently reported detection of HMTV proteins in human breast cancer cells (15) .
Previously, we showed that the signal peptide (98 Nterminal amino acids) of the Env-precursor protein of MMTV is localized in nucleoli of murine T-cell lymphomas that harbor the virus (16, 17) . This peptide was initially named MMTV-p14 (p14, for short) because of its electrophoretic mobility. Its mass was subsequently determined by mass spectrometry to be 11 kDa (17) . The nucleolar localization of p14 is not limited to murine lymphomas, as it also occurs in mouse mammary carcinoma cell lines that harbor MMTV (18) . Cell lines devoid of MMTV (either lymphoma or mammary carcinoma) do not show any cross-reaction with anti-p14 antibodies. Furthermore, using antibodies generated against recombinant p14, this protein was identified in nucleoli of a subset of human breast cancers (18) . Comparing the sequence of p14 with the parallel sequence of a provirus isolated from human breast cancer revealed 86% homology between the two (18) .
N-terminal signal sequences are known to mediate targeting and insertion of nascent secretory and membrane proteins into the endoplasmic reticulum (ER). Following targeting of the 74-kDa envelope protein precursor of MMTV to the ER, the signal sequence is cleaved, and the envelope protein is further glycosylated and processed to give the viral gp52 and gp36 envelope glycoproteins. No additional functions were previously proposed for MMTV-p14, as it was assumed to be degraded. Subsequent to our initial reports, it was shown that p14 is also the signal sequence of a splice variant of MMTV-env (termed REM) functioning as a nuclear export factor for intron-containing transcripts (analogous to the role of HIV-Rev protein; refs. 19, 20) . A recent study suggested a novel pathway, whereby this signal sequence can be released from the ER, accumulate in the nucleoli, and thus, fulfill a posttargeting function in a different compartment (21) . Although a variety of viral proteins, such as HIV-Rev, HTLV-Rex, and others enter the nucleus and accumulate in the nucleoli of infected cells, our studies showed, for the first time, that the signal peptide of a retrovirus envelope protein survives to accumulate in the nucleolus. This was also the first time that any MMTV protein was observed in this compartment. Following these studies, 9 p14-binding proteins have been identified (18) . Four of these B23 (nucleophosmin), L5, La, and acidic ribosomal binding protein are nucleolar proteins involved in a variety of cellular processes. Interestingly, p14 is not an isolated case of a viral signal peptide translocating to the nucleolus: it was recently reported that the human endogenous retrovirus HERV-K (HML-2) encodes a stable signal peptide, analogous to p14, which also localizes in nucleoli (22) . Collectively, these, and our previous findings, support the concept of signal peptides as retroviral modulators of their host cell physiology.
Materials and Methods

Cell culture
All materials were from Invitrogen, unless otherwise noted.
MCF-7 human breast cancer cells (a kind gift of Dr. Nissim Hebrew University of Jerusalem, Department of Genetics) were grown in Dulbecco's modified Eagle's medium, with 10% fetal calf serum, 1% L-glutamine, 50 mg/L streptomycin, and 50,000 units/L penicillin. Cells were grown in culture flasks (Thermo Fisher Scientific) at 37 C in 5% CO 2 . The original aliquot was propagated and frozen in aliquots. All experiments were carried out from these aliquots, which were not grown for more than 3 months. Recombinant cell lines, after selection, were treated the same way.
N-Terminal His-Tagged p14
cDNA clone 66b (16) was used as a template and the PCR fragment corresponding to the p14 sequence was ligated into pET-22b(þ), parallel2 (Novagen). The resulting plasmid was confirmed by sequencing and the expressed His-tagged p14 protein was purified on a TALON (Clontech) affinity column and purity confirmed as previously shown (18) .
Eukaryotic expression of p14
cDNA clone 66b was also used as a basis for eukaryotic expression. The sequence was ligated into the pTRE2hyg plasmid, validated, and transfected into MCF-7 cells containing the pTet-off plasmid (Tet-off Gene Expression System; Clontech). In this system, addition of doxycycline, a tetracycline derivative, turns off expression of the plasmid. Expression of p14 was confirmed and the cells cloned. Mutations (Fig. 1A) were created with the primers listed in Supplementary Tables S1 and S2, using the QuikChange II site directed mutagenesis kit from Agilent Technologies.
Western blots
Cells were lysed by SDS-PAGE sample buffer, separated by 15% SDS-PAGE, and transferred to nitrocellulose. p14 (and p21) was visualized using the polyclonal anti-p14 antibody (18) , horseradish peroxidase-linked donkey anti- 
Immunoprecipitation and immunofluorescence
These were carried out as previously described (19, 20) In vitro phosphorylation assays PKC. Ten mg of recombinant p14 (see above) or of Histone (Sigma) was incubated with 2.5 ng of PKC (EMD Chemicals) in the presence of 1.25 mmol/L EGTA, 50 mmol/L MES (pH ¼ 6), 12.5 mmol/L MgCl 2 , and 1 mmol/L ATP at 30 C for 1 hour. Phosphorylation was determined by Western blot using a-phosphoserine antibodies (Abcam, Inc.,).
CK2. Ten mg of recombinant p14 was incubated with 500 U of CK2 (New England Biolabs) using buffer supplied with addition of 1 mmol/L ATP at 30 C for 1 hour. Phosphorylation was determined by Western blot as described above.
Fluorescence recovery after photobleaching
MCF-7 cells expressing GFP-p14 were grown in standard conditions. Individual nucleoli were photobleached and the fluorescent recovery of p14 in the nucleolus was followed using an FV-1000 confocal microscope (Olympus).
Heterokaryon assay
This was done as described (23) . MCF-7 and NIH-3T3 cells were plated together. The medium was replaced with 300-mL medium containing 100 mg/mL cycloheximide. After 30 minutes, 300 mL of 50% PEG3350 (Sigma) was added for 105 seconds at room temperature. Wells were washed 3Â with PBS, and growth medium containing 100 mg/mL cycloheximide was added. Cells were incubated at 37 C, 5% CO 2 for 4 hours and analyzed by immunofluorescence as described above, except that nuclei were stained with Hoechst (Sigma). When leptomycin B (30 ng/mL) (Invitrogen) was added, the incubation times were 2.5 hours before PEG addition and 5 hours after.
MCF-7 cell injection into severe combined immunodeficient mice
MCF-7 cells (naive or ectopically expressing p14) were washed and resuspended in PBS at 2 Â 10 6 cells/100 mL. Fifty mL was injected bilaterally into each of the third mammary fat pads of female severe combined immunodeficient (SCID) Balb/c mice aged 6 to 8 weeks (Harlan, Israel). Mice were held in an SPF facility (AAALAC accreditation #1285), treated and euthanized following ulceration of the tumors in accordance with NIH guidelines.
Microarray analysis
Total RNA isolation was done with the perfect pure RNA cell & tissue kit (5PRIME). Purity and concentration were determined by absorbance and by RNA gel electrophoresis. For hybridization to the GeneChip Human Gene 1.0 ST Array (28,869 genes; Affymetrix), 2 independent RNA preparations were made from each of the tested MCF-7 lines. Microarray raw data are in the Supplementary Files.
Statistical analysis of microarrays was carried out with assistance of The Genomic Data Analysis Unit of Hadassah Medical School, Hebrew University of Jerusalem. The normalized mean of the mRNA sample repeats was compared with the control cells mean using a threshold of 2-fold or more and P value of 0.05 or less. The resultant gene lists were subjected to cross analysis and visualized using a Volcano diagram (Partec Genomics Suite, Partec Inc.). These genes were further analyzed using the Ontoexpress pathway program (http://vortex.cs.wayne.edu) and individual gene examination, to identify genes or pathways that were significantly affected by the presence of p14.
Quantitative real-time PCR
Quantitative real-time PCR intron spanning primers were designed, using Primer Express 2.0, for the selected genes,
, and the housekeeping gene GAPDH (glyceraldehyde-3-phosphate dehydrogenase; F:
, with expected product sizes of 100 to 130 bp. RNA was then treated with DNAse and reverse transcribed with SuperScript First-Strand cDNA Synthesis kit (Invitrogen). Amplification was conducted using KAPA SYBR FAST (Kapa Biosystems), according to the standard mix protocol. The samples were run using ABI prism 7900HT machine (Applied Biosystem). Protocol consisted of 2 minutes, 50 C reverse transcriptase followed by 10 minutes at 95 C, 40 cycles of 15 seconds at 95 C, and 1 minute at 60 C were carried out. A melting curve was used to confirm the specificity of the PCR products. Experiments were carried out in triplicates.
PCR reaction efficiency was calculated for each primer pair with 5 dilution points of the calibrator sample to validate primers. Fold change in expression of each gene was calculated using the DDC t method. DDC t ¼ [Target gene in p14 sample -housekeeping gene in the same sample]-[Target gene in control -housekeeping gene in control]. Fold change ¼ 2 ÀDDC t (24) . Significance of the data was confirmed using t-test.
Results
In view of the recent findings on MMTV involvement in breast cancer and the immune reactivity of some breast cancer tissue arrays toward anti-p14 antibodies (6, 18), we examined the role of p14 in the biology of breast cancer cells devoid of MMTV. Inducibly expressed p14 was transfected into MCF-7 cells as described in Materials and Methods.
Immunofluorescence and Western blot analysis of the p14-expressing cell line showed that p14 was expressed and localized in the nucleolus ( Fig. 1C and F) , similar to its localization in murine lymphomas and mammary carcinomas that harbor MMTV ( Fig. 1E and F and ref. 18 ). As expected, incubation of this cell line with doxycycline reduced p14 expression to very low levels ( Fig. 1D and F) . Nevertheless, the obvious leakiness of the system prevented us from using doxycycline-treated cells as internal negative controls.
Intracellular localization of mutant p14s
The p14 amino acid sequence was analyzed using the Prosite (www.expasy.org/tools/scanprosite) and MyHits (http://myhits.isb-sib.ch/cgi-bin/motif_scan) sites to determine putative functional motifs (17) . We then created MCF-7 cell lines stably expressing a battery of mutated p14 sequences that include point mutations at putative posttranslational modification and nuclear localization sites (NLS) and deletions along the sequence of p14, including the NLS region (Fig. 1A ). These were double-stained for p14 and B23, a nucleolar shuttling protein that also binds p14 (17, 18) . As can be seen in Fig. 2 , wild-type p14 localized into the nucleolus, colocalizing with B23. The mutations in the region of the NLS, however, showed a gradient of differing localization profiles (Fig. 2) . The double point mutation HH NLS, in which histidines replaced 2 consecutive basic amino acids (R 32 R 33 ) in the first half of the bipartite NLS, showed some relocalization out of the nucleolus and into the nucleus. The double point mutation ED NLS, in which glutamate and aspartate replaced 2 consecutive basic amino acids (K 31 R 32 ), was localized to the nucleus to a larger extent. Deletion of the first half of the NLS (R 29 -R 34 ) moved almost all of the p14 out of the nucleolus, leaving the majority in the nucleus, with a significant amount of the mutant p14 remaining in the cytoplasm. Deletion of the entire NLS (R 29 -R 45 ) resulted in all of the p14 remaining in the cytoplasm. This confirms that the sequence previously identified as the NLS is responsible for localization of p14, not only to the nucleus but also to the nucleolus. Mutations outside of the NLS (including the putative CK2 and PKC phosphorylation sites) did not affect p14 localization to the nucleolus (not shown). We also found that stop codon mutations (Fig. 1A) did not express well enough to warrant further experiments.
Binding of p14 to B23
The different p14 mutants were further tested as to their binding capacity to B23. Figure 3A shows that B23 coimmunoprecipitates with p14-wt, as well as with the PKC À mutant (and all other deletion mutants-not shown), but not with CK2
À and del1 mutants. To confirm this result, B23 was immunoprecipitated and the resultant immunoprecipitate Western blotted versus a-p14 antibodies (Fig. 3B) . In this experiment, too, CK2
À and del1 mutations showed no interaction with B23. These findings suggested that Serine 65 in the putative CK2 phosphorylation site is involved in the interaction with B23. The del1 sequence also participates in the interaction with B23. However, because the mutation S18A in the putative PKC phosphorylation site (included in the del1 sequence, see Fig. 1A ) is not involved in B23 binding, it is likely that a shorter sequence of del1 participates in this interaction.
Dynamics and nuclear export of p14
To determine the mobility of p14 within the nucleus, MCF-7 cells were stably transfected with a GFP-p14 expressing plasmid and subjected to fluorescence recovery after photobleaching (FRAP). The mobility of p14 was high, and recovery was essentially complete within a minute (Fig. 4A) . A similar observation (recovery within a minute) was made upon transfection of Hela cells with GFP-p14 and with Rev-GR-GFP in a well described nuclear import export assay as a control (not shown). To study the nuclear export of p14, heterokaryon analysis was applied. To that effect, p14-expresssing MCF-7 cells were fused with NIH-3T3 cells (murine origin with no MMTV background). The nuclei of these 2 cell types can be visually distinguished (23) , so that the export of p14 from human to murine nuclei in the heterokaryon can be monitored. As can be seen in Fig. 4B , the export of p14 from MCF-7 nuclei to NIH-3T3 nuclei in the fused cells was identifiable, whether the MCF-7 cells were expressing p14-wt, CK-2 À , or del1 mutations. Note also that the nuclei of the mouse-mouse heterokaryon in the CK2 panel are devoid of p14. Identical results were seen with MCF-7 cells expressing PKC À and DEL2 mutations (not shown). As B23 does not bind to the CK2 À and del1 mutant p14s (see Fig. 3 ), these findings suggested that B23 is not involved in the nuclear export of p14. Leptomycin B, an inhibitor of nuclear export, prevented the accumulation of p14 in the murine nuclei of the heterokaryons (Fig. 4B) , indicating that p14 is actively exported from the nucleus via a CRM1-dependent mechanism (19) .
p14 is a phosphoprotein
To determine whether the putative CK2 and PKC sites of p14 are endogenously phosphorylated, ectopically expressed p14 wild type and the point mutations Ser18Ala (PKC À ) and Ser65Ala (CK2 À ) were immunoprecipitated from MCF-7 cell extracts with a-p14 antibodies. The phosphorylation level of these proteins was determined by Western blot using a-phophoserine antibodies. As can be seen in Fig. 5A , although both wild type and the 2 mutant proteins were phosphorylated, the wild-type p14 was more highly phosphorylated than either mutant alone. A double mutant (Ser18Ala, Ser65Ala) containing point mutations in both serines was not phosphorylated endogenously (Fig. 5A) . These findings were consistent with both serines being endogenously phosphorylated.
We next attempted to phosphorylate the PKC À and CK2
À mutants in vitro, using purified CK2 and PKC enzymes (see Materials and Methods). As can be seen in Fig. 5B , CK2 could phosphorylate the purified p14. PKC does not seem to phosphorylate p14 in vitro, suggesting that another serine kinase may be involved in phosphorylation of this site. Taken together, these findings are consistent with p14 being phosphorylated by different kinases at serines 18 and 65. In addition, preliminary results in our laboratory have indicated that the ribosomal protein L5 is differentially immunoprecipitated with the various phosphorylation mutants of p14.
The phosphorylation state of p14 alters tumorigenicity
The phosphorylation mutants (PKC À , CK2 À , and double mutant PKC À -CK2 À ), as well as wt-p14 expressing, and naive MCF-7 cells, were injected (1 Â 10 6 cells) into each of 2 mammary fat pads of female SCID mice and followed thereafter for development of progressive tumors (see Materials and Methods). This inoculum of cells was chosen because it allows us to analyze whether mutant p14s either impair or enhance the tumorigenicity of affected cells relative to naive MCF-7 cells.
MCF-7 cells expressing the p14-PKC À construct developed progressive tumors in all mice (n ¼ 5) (Fig. 5C ). In one of these mice, tumor cells infiltrated the anterior chambers of both eyes, thus pointing toward enhanced metastatic potential of MCF-7 cells expressing p14 with the PKC À mutation. On the other hand, mice injected with either CK2 À or double CK2
À -PKC À mutants did not develop any tumors for at least 150 days, when the experiment was terminated. Both naive MCF-7 and p14 wt cells developed progressive tumors in 3 of 5 mice. The time course of tumor appearance in the p14 wt-injected group was delayed relative to the naive MCF-7 cells. However, 2 mice from the p14 wtinjected group developed solid tumors distant from the sites of inoculation.
A c 2 test indicates that the proportions of tumor-positive mice are not the same among the 5 different cell types (x 2 4 ¼ 15:26 P ¼ 0.0025). Due to the relatively small sample size (N ¼ 5), the P value was estimated by computer simulations-10 4 random samples were drawn under the null assumption of independence between treatments and tumor-positive mice, and the proportion of samples with a c 2 value larger than or equal to the observed c 2 statistic was taken as an estimate of the real P value.
More specifically, the proportion of tumor-positive mice injected with p14 PKC À cells is significantly larger than the proportions for those injected with p14 CK2 À and double mutant cells (Fisher exact test, P ¼ 0.004), whereas the proportions for mice injected with naive and p14 wt cells have an intermediate value (though not significantly different from the 2 extremes).
The above findings are consistent with the notion that the phosphorylation status of p14 is instrumental for regulating the tumorigenic potential (both positively and negatively) of MCF-7 cells that express this protein. We note that CK2 overexpression has been linked to increased tumorigenicity in murine cancer (10) .
Transcriptional regulation by p14
The above findings linking phosphorylation of p14 to tumorigenic potential prompted us to further examine the molecular basis of these changes. L5 was previously identified by us as a target protein for p14 (18) . It also binds MDM2 in response to nucleolar stress (25) , and another p14 target, B23, which is essential for the nuclear export of L5 (23) . We attempted to determine whether L5 would be differentially expressed by cells expressing either p14 wt or the various phosphorylation mutants. Real-time PCR (Fig.  6D) showed a 2-fold increase in L5 RNA in MCF-7 cells expressing p14-wt (relative to naive MCF-7 cells), whereas in MCF-7 cells expressing p14-PKC À , L5 showed a 6.7-fold increase in transcription compared with naive MCF-7 cells. CK2
À cells showed a 1.5-fold decrease (relative to naive MCF-7 cells) in L5 RNA. Thus the ratio of L5 expression in PKC À cells to CK2 À is approximately 10-fold. To test whether expression of p14 and its phosphorylation variants play a more extensive role in transcriptional regulation, RNA was extracted from independent duplicates of MCF-7 cells stably expressing the WT, PKC À , or CK2 À mutant p14s and subjected to microarray analysis (see Materials and Methods). As the PKC À and the CK2 À cells showed the opposite extremes of tumorigenicity (see Fig.  5C ), the transcriptional profile of these 2 cell lines were compared. Volcano analysis of the data (Fig. 6A) shows that 142 genes (Supplementary Table S3 ) are transcriptionally regulated (up, down) by the PKC À versus CK2 À mutant p14s. The 18 most statistically significant genes, along with their cellular functions, are listed in Table 1 . Figure 6B and C is a graphical analysis of the absolute expression of these genes in the 4 cell types. As can be seen, the differences in the expression profile are not random, as the changes in gene expression are mostly specific to a particular cell line. Thus, most of the genes with a higher expression profile in CK2 À (or PKC À ) cells are higher only in CK2 À (or PKC À ) cells. The EGF receptor, ErbB4, was chosen for quantitative confirmation of the chip analysis. This gene was found to change significantly (decrease more than 10-fold in the microarray analysis) only in the CK2 À mutant cells (Fig.  6C ). In addition, many of the components of the ErbB4-signaling pathway-6 of 14, as well as 11 of 87 components of the more intricate ErbB pathway were found to be differentially expressed in the various transfectants (see Supplementary Data). Furthermore, it was found that an integration site in cells infected with MMTV was in an intron of ErbB4 (Stanislav Indik and Walter H. Gunzburg; Personal Communication). These pathways are instrumental in growth control of mammalian cells, as well as in mammary carcinogenesis and breast cancer. Real-time PCR (Fig. 6D) showed a small (1.3-fold A, whole-cell extracts of MCF-7 cells expressing wild-type or mutant p14 were immunoprecipitated with a-p14 antibodies and then analyzed by Western blot using a-phosphoserine antibodies. B, His-tagged p14 (wild type) was expressed in bacteria and purified. Phosphorylation with CK2 and PKC was carried out as described in Materials and Methods and the results analyzed by Western blot using a-phosphoserine antibodies. C, tumor development after injection of MCF-7 cells expressing wild-type or p14 phosphorylation mutants into mammary fat pads of SCID mice. MCF-7 cells expressing wild-type or mutant p14 were injected bilaterally into mammary fat pads of SCID mice and development of tumors followed as described in Materials and Methods. À expressing cells. Note that L5 is not only transcriptionally regulated by p14 but is also a binding partner of p14 (18) .
Thus, the phosphoprotein p14, when ectopically expressed in MCF-7 cells lacking MMTV, modulates tumorigenicity. Phosphorylation of p14 seems to be a critical regulator of this process. Mutants lacking the CK2 phosphorylation site show diminished tumorigenic potential. This mutation is also associated with transcriptional deregulation of the ErbB signal transduction pathway and changes in the expression of nucleolar/ribosomal genes. These findings suggested that p14 acts independently of other MMTV viral products to induce changes in cellular physiology.
Discussion
The signal peptide of the Env-precursor protein of MMTV, p14, is localized to the nucleoli of cells that contain the whole virus or transgenically express p14. Furthermore, p14 is a highly mobile phosphoprotein within the nucleus, and its nuclear export is CRM1 dependent and independent of its nucleolar target protein B23. The phosphorylation status of Serines 18 and 65 play critical roles in modulating the tumorigenic potential of MCF-7 cells that express p14. Expression of p14 alters transcription of a number of genes, including the ribosomal protein L5 (a formerly defined target of p14) and the ErbB4 pathway involved in breast cell growth and differentiation. The expression levels of these In recent years, it has been established that in addition to its role in rRNA synthesis and ribosome biogenesis, the nucleolus is involved in a variety of cellular functions, including regulation of the cell cycle, senescence, gene silencing, and sensing of cellular stress (26) (27) (28) (29) (30) (31) , as well as in viral replication (32, 33) . The relationship between the nucleolus, ribosome biogenesis, and cancer has been the topic of a recent review (34) , in which some evidence to that effect has been documented. Still, the authors caution that most of the proteins involved in ribosome biogenesis (B23 for example) have extraribosomal functions that may support tumorigenesis, independent of ribosome function and mRNA translation.
Although a variety of viral proteins are translocated into the nucleolus following viral infection (33), we were the first to show that the signal peptide of MMTV-Env precursor is also localized to this compartment (16, 17) . It turns out that this is not an isolated case, as it was recently shown that the leader sequence of HERV-K is also localized in the nucleolus (22) . Thus, it cannot be excluded that other viral signal sequences may be targeted to the nucleolus.
Previously, the nucleolar proteins B23 (nucleophosmin, numatrin, and NO38) and L5 have emerged as proteins interacting with p14 (18) . Here, we extended these findings by defining those p14 domains involved in B23 binding. One of these is Ser65 in the CK2 phosphorylation site. Thus, it is likely that phosphorylation of this Serine by CK2 enhances B23 binding to subsequently regulate B23-related functions. B23 is a multifunctional nucleolar phosphoprotein that shuttles continuously between the cytoplasm and nucleolus. It is essential for ribosome biogenesis and is thought to act as both a proto-oncogene and a tumor suppressor (35, 36) . Moreover, B23 maintains genomic integrity by controlling DNA repair mechanisms and centrosome duplication during mitosis. It has also emerged as a regulator of the p53/p14ARF/MDM2 pathway, stabilizing p53, thus playing a role in mediating the cellular stress response (35, (37) (38) (39) . B23 has been strongly implicated in hematopoietic malignancies, in which translocations and mutations involving the gene have been reported in various lymphomas and leukemias, giving rise to fusion proteins or mutant products (40) .
For ribosomal protein L5, quantitative reverse transcriptase PCR (qRT-PCR) findings provide additional support to the previously documented interaction between p14 and this nucleolar protein (18) . Here, the level of L5 mRNA directly correlates with the tumorigenicity of MCF-7 cells transfected with different p14 mutations, consistent with transcriptional regulation of L5 by p14. The ribosomal L5 protein is a 60S subunit protein that chaperones the 5S rRNA into the nucleolus and out into the cytosol (41) . Interestingly, B23 has been shown to directly interact with L5 and play an essential role in its nuclear export (23) . Interaction of these 2 proteins in a more general context was reported recently, when B23 was implicated in directing the nuclear export of both 40S and 60S ribosomal subunit proteins (42) . L5 has also been reported to inhibit MDM2-mediated p53 ubiquitination and degradation, by inhibiting the E3 ubiquitin ligase activity of MDM2 (25, 43, 44) .
Because B23 and L5 both play a role in the regulation of a major stress response pathway and as both molecules interact with MMTV-p14, we propose that, through its interaction with these 2 nucleolar proteins, MMTV-p14 (and therefore MMTV) can affect the cellular stress response and its outcome (including apoptosis, cell-cycle regulation, tumorigenesis and others), thus adding an additional level of complexity to the regulation of these interactions in the nucleus. How the phosphorylation status of p14 is involved in these interactions is presently unknown. In addition to L5, ErbB4 is another gene whose transcriptional regulation by p14 is phosphorylation dependent. The upregulation of ErbB4 transcripts correlates with the tumorigenic potential of MCF-7 cells expressing different p14 mutants. ErbB4 is a member of the EGF receptor family that mediates cell proliferation and differentiation and mammary gland differentiation in response to EGF-like growth factors (45) . In human breast cancer cells, nuclear localization of ErbB4 correlates with poor survival (46) .
Our in vivo findings suggest that p14 may play a role in altering the tumorigenic potential of MMTV-infected cells. This characteristic seems to depend on the phosphorylation status of p14, serine 65 being phosphorylated by CK2.
Because the CK2
À mutant cells show impaired tumorigenicity, it is likely that phosphorylation of serine 65 by this kinase is associated with enhanced tumorigenicity. Indeed, CK2, a highly conserved serine/threonine protein kinase that is ubiquitously distributed in eukaryotes is known to play an important role in promoting tumorigenesis (47) . This is the case for a variety of tumors in which CK2 inhibitors have been applied in an effort to impair tumor growth. By extension, as the PKC À mutant cells show enhanced tumorigenicity, it is possible that phosphorylation of serine 18 of p14 is associated with decreased tumorigenicity. The exact nature of the kinase(s) that phosphorylate(s) serine 18 is not yet defined. Because the double mutant "CK2
À -PKC À " shows impaired tumorigenicity similar to that of the CK2 À mutant cells, the CK2 À mutation seems to exert a dominant negative effect over the PKC À mutation in the context of p14. It is thus tempting to speculate that the balance between the phosphorylation of serine 18 (decreased tumorigenicity) and serine 65 (increased tumorigenicity) could determine whether p14 will act in the capacity of a tumorigenic or antitumorigenic agent. This could alter the oncogenic potential of MMTV in infected target cells, based on the proportion of CK2 to PKC sites phosphorylated.
Katz and colleagues (13) have previously proposed that the Env protein of MMTV may play a role in mammary tumorigenesis. They showed that ectopic expression of MMTV Env in normal mammary epithelial cells resulted in phenotypic transformation, and an activation motif in this protein (the Immunoreceptor Tyrosine-based Activation Motif -ITAM) was critical to that activity. Although subsequent studies (using Env expression in transgenic mice) indicated that ITAM is not sufficient for cellular transformation, Env signaling, nevertheless, takes part in MMTVmediated transformation, as mutation of the ITAM reduces virus-induced mammary tumorigenesis (48, 49) . Taken together, our findings and those of Ross's group are consistent with a role for the Env protein and its signal peptide in regulating the tumorigenic potential of MMTV-infected cells.
MMTV-induced mouse mammary tumors develop following the proviral integration into common integration sites. Genes commonly affected by MMTV insertion in multiple individual tumors include members of the Wnt, Fgf, and Rspo gene families, as well as Notch4 and eIF3e (50) . Activation of these genes is not always sufficient to induce tumorigenesis, and additional events must occur to initiate it (50) . We propose that p14 (with or without ITAM) provides a "missing link" that (following insertional mutagenesis) enhances or impairs (depending on its phosphorylation status) the tumorigenicity of mammary cells infected with MMTV.
The above findings (including transcriptional regulation of cellular genes by p14) suggest a novel strategy whereby retroviruses modulate their host physiology via signal peptides. This modulation may be mediated via nucleolar targeting of such viral signal peptides. In the case of p14, phosphorylation status dictates tumorigenic potential. Thus, at least in the case of MMTV, the signal peptide clearly carries out more functions than previously appreciated.
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